Cadrenal Therapeutics Launches Phase 2a AKI Trial for CAD-1005, Eyes Pharma Partnering to Secure Funding
CVKD is trading near its 52-week low of $3.7 (0.0% above the low) on elevated volume (1.8× avg).
Summary
Cadrenal Therapeutics is launching a Phase 2a clinical trial for its lead drug candidate, CAD-1005, for a new indication: Acute Kidney Injury (AKI). This strategic move aims to attract a well-capitalized pharmaceutical partner and secure non-dilutive funding, which is critical given the company's reiterated going concern warning and cash runway only into October 2026. The AKI market is estimated at $1 billion annually, and the trial's data could also help de-risk the pivotal Phase 3 program for CAD-1005 in heparin-induced thrombocytopenia (HIT), which recently advanced. The company plans to discuss this multi-indication strategy at the upcoming BIO International Convention.
At the time of this announcement, CVKD was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $3.70 to $15.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.